nach oben

Erschienen in:

16.08.2016

An rs13293512 polymorphism in the promoter of let-7 is associated with a reduced risk of ischemic stroke

verfasst von: Li Zhang, Junsu Yang, Qiang Xue, Dong Yang, Yibing Lu, Xuefeng Guang, Weihua Zhang, Ruiqiong Ba, Hongwen Zhu, Xiang Ma

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

The expression of let-7 family members was differentiated in ischemic stroke (IS), functioning as an important regulating molecular in the pathophysiology of stroke. We hypothesized that genetic polymorphism in the promoters of let-7 family may be associated with the risk of IS. To test this hypothesis, we investigated the association of the rs10877887 and rs13293512 in the promoters of let-7 family with the susceptibility to IS. A hospital-based case–control study was performed. The rs10877887 genotype was determined by using a polymerase chain reaction-restriction fragment length polymorphism assay, and the rs13293512 genotype was determined by using a TaqMan assay. We found that the rs13293512CC genotype was associated with a reduced risk of IS (CC vs. TT: adjusted OR = 0.43, 95 % CI 0.26–0.71; dominant model: adjusted OR = 0.70, 95 % CI 0.49–0.98; recessive model: adjusted OR = 0.45, 95 % CI, 0.28-0.73). Stratification analysis showed that the rs10877887TT carriers had a higher level of total cholesterol compared to rs10877887TC/CC carriers (P = 0.03). Combined analysis showed that the rs10877887TC/CC and rs13293512TC/CC genotypes had a reduced risk of IS risk (adjusted OR = 0.58, 95 % CI 0.36–0.95). Our findings suggest that the rs13293512 polymorphism may be a protective factor for the development of IS.

Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O’Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C, Global Burden of Diseases I, Risk Factors S, the GBDSEG (2014) Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 383(9913):245–254PubMedPubMedCentralCrossRef

Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ (2001) Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 103(1):163–182PubMedCrossRef

Warlow CP (1998) Epidemiology of stroke. Lancet 352 Suppl 3:SIII1–SIII4PubMedCrossRef

Holmegard HN, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A, Benn M (2016) Sex hormones and ischemic stroke: a prospective cohort study and meta-analyses. J Clin Endocrinol Metabol 101(1):69–78. doi:10.1210/jc.2015-2687 CrossRef

Liu F, McCullough LD (2012) Interactions between age, sex, and hormones in experimental ischemic stroke. Neurochem Int 61(8):1255–1265. doi:10.1016/j.neuint.2012.10.003 PubMedPubMedCentralCrossRef

Shinton R, Beevers G (1989) Meta-analysis of relation between cigarette smoking and stroke. BMJ 298(6676):789–794PubMedPubMedCentralCrossRef

Markus HS (2010) Genetics studies in ischaemic stroke. Translational stroke research 1(4):238–245. doi:10.1007/s12975-010-0041-5 PubMedCrossRef

Dichgans M (2007) Genetics of ischaemic stroke. Lancet Neurol 6(2):149–161. doi:10.1016/S1474-4422(07)70028-5 PubMedCrossRef

Flossmann E, Schulz UG, Rothwell PM (2005) Potential confounding by intermediate phenotypes in studies of the genetics of ischaemic stroke. Cerebrovasc Dis 19(1):1–10. doi:10.1159/000081905 PubMedCrossRef

10.

Flossmann E, Schulz UG, Rothwell PM (2004) Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 35(1):212–227. doi:10.1161/01.STR.0000107187.84390.AA PubMedCrossRef

11.

Schulz UG, Flossmann E, Rothwell PM (2004) Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke 35(4):819–824. doi:10.1161/01.STR.0000121646.23955.0f PubMedCrossRef

12.

Meschia JF, Atkinson EJ, O’Brien PC, Brott TG, Brown RD Jr, Hardy J (2003) Familial clustering of stroke according to proband age at onset of presenting ischemic stroke. Stroke 34(7):e89–e91. doi:10.1161/01.STR.0000078312.07274.A4 PubMedCrossRef

13.

Mathonnet G, Fabian MR, Svitkin YV, Parsyan A, Huck L, Murata T, Biffo S, Merrick WC, Darzynkiewicz E, Pillai RS, Filipowicz W, Duchaine TF, Sonenberg N (2007) MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science 317(5845):1764–1767. doi:10.1126/science.1146067 PubMedCrossRef

14.

Soreq H, Wolf Y (2011) NeurimmiRs: microRNAs in the neuroimmune interface. Trends in molecular medicine 17(10):548–555. doi:10.1016/j.molmed.2011.06.009 PubMedCrossRef

15.

Vickers KC, Remaley AT (2010) MicroRNAs in atherosclerosis and lipoprotein metabolism. Curr Opin Endocrinol Diabetes Obes 17(2):150–155. doi:10.1097/MED.0b013e32833727a1 PubMedPubMedCentralCrossRef

16.

Gubern C, Camos S, Ballesteros I, Rodriguez R, Romera VG, Canadas R, Lizasoain I, Moro MA, Serena J, Mallolas J, Castellanos M (2013) miRNA expression is modulated over time after focal ischaemia: up-regulation of miR-347 promotes neuronal apoptosis. FEBS J 280(23):6233–6246. doi:10.1111/febs.12546 PubMedCrossRef

17.

Jeyaseelan K, Lim KY, Armugam A (2008) MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke 39(3):959–966. doi:10.1161/STROKEAHA.107.500736 PubMedCrossRef

18.

Selvamani A, Williams MH, Miranda RC, Sohrabji F (2014) Circulating miRNA profiles provide a biomarker for severity of stroke outcomes associated with age and sex in a rat model. Clin Sci 127(2):77–89. doi:10.1042/CS20130565 PubMedPubMedCentralCrossRef

19.

Jickling GC, Ander BP, Zhan X, Noblett D, Stamova B, Liu D (2014) microRNA expression in peripheral blood cells following acute ischemic stroke and their predicted gene targets. PLoS One 9(6):e99283. doi:10.1371/journal.pone.0099283 PubMedPubMedCentralCrossRef

20.

Sorensen SS, Nygaard AB, Nielsen MY, Jensen K, Christensen T (2014) miRNA expression profiles in cerebrospinal fluid and blood of patients with acute ischemic stroke. Transl Stroke Res 5(6):711–718. doi:10.1007/s12975-014-0364-8 PubMedCrossRef

21.

Wang W, Sun G, Zhang L, Shi L, Zeng Y (2014) Circulating microRNAs as novel potential biomarkers for early diagnosis of acute stroke in humans. J Stroke Cerebrovasc Dis 23(10):2607–2613. doi:10.1016/j.jstrokecerebrovasdis.2014.06.002 PubMedCrossRef

22.

Li SH, Su SY, Liu JL (2015) Differential Regulation of microRNAs in Patients with Ischemic Stroke. Curr Neurovascular Res 12(3):214–221CrossRef

23.

Long G, Wang F, Li H, Yin Z, Sandip C, Lou Y, Wang Y, Chen C, Wang DW (2013) Circulating miR-30a, miR-126 and let-7b as biomarker for ischemic stroke in humans. BMC neurology 13:178. doi:10.1186/1471-2377-13-178 PubMedPubMedCentralCrossRef

24.

Ni J, Wang X, Chen S, Liu H, Wang Y, Xu X, Cheng J, Jia J, Zhen X (2015) MicroRNA let-7c-5p protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia activation. Brain Behav Immun 49:75–85. doi:10.1016/j.bbi.2015.04.014 PubMedCrossRef

25.

Peng G, Yuan Y, Wu S, He F, Hu Y, Luo B (2015) MicroRNA let-7e is a potential circulating biomarker of acute stage ischemic stroke. Transl Stroke Res 6(6):437–445. doi:10.1007/s12975-015-0422-x PubMedCrossRef

26.

Selvamani A, Sathyan P, Miranda RC, Sohrabji F (2012) An antagomir to microRNA Let7f promotes neuroprotection in an ischemic stroke model. PLoS One 7(2):e32662. doi:10.1371/journal.pone.0032662 PubMedPubMedCentralCrossRef

27.

Liu Y, Zhang Y, Wen J, Liu L, Zhai X, Liu J, Pan S, Chen J, Shen H, Hu Z (2012) A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS One 7(2):e32230. doi:10.1371/journal.pone.0032230 PubMedPubMedCentralCrossRef

28.

Li L, Pan X, Li Z, Bai P, Jin H, Wang T, Song C, Zhang L, Gao L (2013) Association between polymorphisms in the promoter region of miR-143/145 and risk of colorectal cancer. Hum Immunol 74(8):993–997. doi:10.1016/j.humimm.2013.04.019 PubMedCrossRef

29.

Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, Liu S, Liu Z, Shi H, Shen H, Hu Z (2011) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128(2):412–417. doi:10.1002/ijc.25342 PubMedCrossRef

30.

Li L, Wu J, Sima X, Bai P, Deng W, Deng X, Zhang L, Gao L (2013) Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol 34(3):1919–1923. doi:10.1007/s13277-013-0736-9 PubMedCrossRef

31.

Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, Zhu YH, Zhang L (2013) A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem 394(3):415–420. doi:10.1515/hsz-2012-0297 PubMedCrossRef

32.

Thayanithy V, Sarver AL, Kartha RV, Li L, Angstadt AY, Breen M, Steer CJ, Modiano JF, Subramanian S (2012) Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone 50(1):171–181. doi:10.1016/j.bone.2011.10.012 PubMedCrossRef

33.

Xie K, Liu J, Zhu L, Liu Y, Pan Y, Wen J, Ma H, Zhai X, Hu Z (2013) A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol 37(6):998–1002. doi:10.1016/j.canep.2013.09.005 PubMedCrossRef

34.

Wang Y, Wei T, Xiong J, Chen P, Wang X, Zhang L, Gao L, Zhu J (2015) Association Between Genetic Polymorphisms in the Promoter Regions of Let-7 and Risk of Papillary Thyroid Carcinoma: a Case-Control Study. Medicine 94(43):e1879. doi:10.1097/MD.0000000000001879 PubMedPubMedCentralCrossRef

35.

Liang Y, Zhao G, Sun R, Mao Y, Li G, Chen X, Gao L, Hu Z (2015) Genetic variants in the promoters of let-7 family are associated with an increased risk of major depressive disorder. J Affect Disord 183:295–299. doi:10.1016/j.jad.2015.04.035 PubMedCrossRef

36.

Sima X, Sun H, Zhou P, You C (2015) A potential polymorphism in the promoter of let-7 is associated with an increased risk of intracranial aneurysm: a case-control study. Medicine 94(51):e2267. doi:10.1097/MD.0000000000002267 PubMedPubMedCentralCrossRef

37.

Chen P, Sun R, Pu Y, Bai P, Yuan F, Liang Y, Zhou B, Wang Y, Sun Y, Zhu J, Zhang L, Gao L (2015) Pri-Mir-34b/C and Tp-53 polymorphisms are associated with the susceptibility of papillary thyroid carcinoma: a case-control Study. Medicine 94(38):e1536. doi:10.1097/MD.0000000000001536 PubMedPubMedCentralCrossRef

38.

Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. trial of org 10172 in acute stroke treatment. Stroke 24(1):35–41PubMedCrossRef

39.

Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403(6772):901–906. doi:10.1038/35002607 PubMedCrossRef

40.

Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Muller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408(6808):86–89. doi:10.1038/35040556 PubMedCrossRef

Titel: An rs13293512 polymorphism in the promoter of let-7 is associated with a reduced risk of ischemic stroke
verfasst von: Li Zhang
Junsu Yang
Qiang Xue
Dong Yang
Yibing Lu
Xuefeng Guang
Weihua Zhang
Ruiqiong Ba
Hongwen Zhu
Xiang Ma
Publikationsdatum: 16.08.2016
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 4/2016
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-016-1400-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant

Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory

Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study)

Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation

Expression of tissue factor and forkhead box transcription factor O-1 in a rat model for chronic thromboembolic pulmonary hypertension